LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Book ; Online: Morbidity in primary care

    Luijks, Hilde / Van de Laar, Floris Alexander / Schers, Henk

    Epidemiologic data from Family Medicine Network

    2023  

    Keywords Care of the elderly ; Family & health ; General practice ; Geriatric medicine ; Hospital infections ; Mental health services ; Oncology ; Paediatric medicine ; Child care & upbringing ; Psychiatry ; Psychology ; Complaints; Family medicine; General practice; Symptoms; Primary care; Prognosis; Diseases; Practice Based Research Network; Epidemiology
    Language English
    Size 1 electronic resource (120 pages)
    Publisher Radboud University Press
    Publishing place Nijmegen
    Document type Book ; Online
    Note English
    HBZ-ID HT030612629
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes

    Floris Alexander van de Laar

    Vascular Health and Risk Management, Vol 2008, Iss Issue 6, Pp 1189-

    2008  Volume 1195

    Abstract: Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department ...

    Abstract Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The NetherlandsAbstract: Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.Keywords: alpha-glucosidase inhibitors, type 2 diabetes mellitus, impaired glucose tolerance
    Keywords Diseases of the circulatory (Cardiovascular) system ; RC666-701 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Cardiovascular ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 616
    Language English
    Publishing date 2008-10-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.

    van de Laar, Floris Alexander

    Vascular health and risk management

    2008  Volume 4, Issue 6, Page(s) 1189–1195

    Abstract: Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are ... ...

    Abstract Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.
    MeSH term(s) Blood Glucose/drug effects ; Diabetes Complications/prevention & control ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/enzymology ; Enzyme Inhibitors/therapeutic use ; Glycated Hemoglobin A/metabolism ; Glycoside Hydrolase Inhibitors ; Humans ; Hypoglycemic Agents/therapeutic use ; Treatment Outcome
    Chemical Substances Blood Glucose ; Enzyme Inhibitors ; Glycated Hemoglobin A ; Glycoside Hydrolase Inhibitors ; Hypoglycemic Agents ; hemoglobin A1c protein, human
    Language English
    Publishing date 2008-11-10
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2186568-1
    ISSN 1178-2048 ; 1176-6344
    ISSN (online) 1178-2048
    ISSN 1176-6344
    DOI 10.2147/vhrm.s3119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6066: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Diabetes: glycaemic control in type 2 (drug treatments).

    Gorter, Kees J / van de Laar, Floris Alexander / Janssen, Paul G H / Houweling, Sebastian T / Rutten, Guy E H M

    BMJ clinical evidence

    2012  Volume 2012

    Abstract: Introduction: Diabetes mellitus is a progressive disorder of glucose metabolism. It is estimated that about 285 million people between the ages of 20 and 79 years had diabetes worldwide in 2010, or 5% of the adult population. Type 2 diabetes may occur ... ...

    Abstract Introduction: Diabetes mellitus is a progressive disorder of glucose metabolism. It is estimated that about 285 million people between the ages of 20 and 79 years had diabetes worldwide in 2010, or 5% of the adult population. Type 2 diabetes may occur with obesity, hypertension, and dyslipidaemia (the metabolic syndrome), which are powerful predictors of cardiovascular disease. Without adequate blood-glucose-lowering treatment, blood glucose levels may rise progressively over time in people with type 2 diabetes. Microvascular and macrovascular complications may develop.
    Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of blood-glucose-lowering medications in adults with type 2 diabetes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
    Results: We found 194 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
    Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: alpha-glucosidase inhibitors (AGIs), combination treatment (single, double, and triple), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, insulins (including conventional [human] and analogue, different regimens, different length of action), meglitinides, metformin, sulphonylureas, and thiazolidinediones.
    MeSH term(s) Blood Glucose/drug effects ; Diabetes Mellitus, Type 2/blood ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Metformin/therapeutic use
    Chemical Substances Blood Glucose ; Hypoglycemic Agents ; Glucagon-Like Peptide 1 (89750-14-1) ; Metformin (9100L32L2N)
    Language English
    Publishing date 2012-10-11
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 2393858-4
    ISSN 1752-8526 ; 1757-0816 ; 1475-9225
    ISSN (online) 1752-8526
    ISSN 1757-0816 ; 1475-9225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 2172: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top